J&J commits $125M in bet that Xencor’s bispecific antibody has an edge in blood cancers
Clinical-stage Xencor is receiving $100 million up front and a $25 million equity investment, while Johnson & Johnson’s Janssen Biotech subsidiary gets global rights to […]